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ABSTRACT: 
HIV infection elicits dysregulation of the immune system and is associated with a 
number of comorbidities.  A common link among HIV-associated comorbidities is monocyte and 
macrophage activation, accumulation, and high turnover.  Anti-retroviral therapy (ART), while 
useful in preventing HIV infection from progressing to immune dysfunction characterized by 
AIDS, does not eliminate infection.  Even with ART, individuals retain a low level of virus that 
is able to reseed infection and a higher rate of comorbidities than uninfected people.  Prior 
research has revealed an inflammatory monocyte/macrophage cell population that is uniquely in 
tissues with infection in an HIV model that uses simian immunodeficiency viral (SIV) infection 
of rhesus macaques.  This cell type is characterized by expression of the inflammatory marker 
calprotectin.   
Through measurements of soluble calprotectin present in the plasma of SIV-infected 
rhesus macaques, I found that calprotectin levels remained low within the first two weeks of 
infection, sharply increased around three weeks post-infection, typically increased to a maximum 
during late stage chronic disease, and positively correlated with plasma viral load.  Initial 
calprotectin levels suggests a trend that high pre-infection levels are associated with not 
progressing to AIDS or SIV encephalitis.  Through immunostaining monocytes and flow 
cytometry, I found that calprotectin expression on classical, intermediate, and non-classical 
monocytes initially decreases with SIV infection, rebounds for most of infection, and sharply 
decreases again with late-stage chronic disease.  Flow cytometry further showed that the 
calprotectin-expressing monocyte expresses CD163, CD169, and CCR2, but lacks expression for 
CX3CR1 and CCR5.  Analysis of RNAseq data illustrates trends that suggest an increase in gene 
expression of genes involved in antiviral/antibacterial and chemotactic functions during 
conditions when calprotectin gene expression is also increasing.  In summary, the data presented 
in this thesis suggest that the calprotectin-expressing monocyte/macrophage may come from an 
intermediate monocyte and play a role in inflammation through calprotectin secretion, activation, 
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CHAPTER 1:  INTRODUCTION 
1.1 HIV 
HIV infection is characterized by three phases:  an acute phase with sharply decreasing 
blood CD4+ T cell levels and a sharp rise and subsequent drop in plasma viral load, an 
asymptomatic phase with gradually increasing viral load and gradually decreasing blood CD4+ T 
cells, and, finally, acquired immune deficiency syndrome (AIDS), which is defined by a blood 
CD4+ T cell count dropping below 200 cells per cubic milliliter and is often accompanied by an 
increase in plasma viral load (1) (see Figure 1 below).  Cells expressing CD4 and either the 
coreceptor CCR5 or CXCR4 are susceptible to HIV infection, making activated CD4+ T 
lymphocytes the primary target of HIV infection.  However, blood monocytes and tissue 
macrophages are also capable of sustaining HIV infection (1), with potential for productive viral 
infection only after monocyte differentiation into macrophages (2).  Antiretroviral therapy (ART) 
results in increases in CD4+ T cells and a reduction of virus to below detection in most assays 
(1).  However, despite viral suppression with ART, chronic HIV-associated comorbidities persist 







Figure 1.  Viral load and CD4 Cell Count in HIV Infection, Untreated and ART Treatment.  Panel A 
shows the three phases of HIV infection without treatment:  acute, asymptomatic, and AIDS.  Acute 
infection is characterized by decreases in CD4+ T cells in the blood and gastrointestinal tract and an 
increasing viral load with peak viral load around six weeks after infection.  Asymptomatic infection is 
characterized byfurther decreases in CD4+ T cells in the blood and gastrointestinal tract, and a gradual 
increase in viral load.  Immune dysregulation that accompanies AIDS is associated with a more rapid 
viral load increase as CD4+ T cells in the blood and gastrointestinal tract strongly decreases.  Panel B 
shows the effect of ART on HIV infection.  ART adherence results in a decrease in viral load to below the 
limit of detection of commercial assays, but not 0, evidenced by viral rebound with ART cessation.  ART 
adherence also results in increases in CD4+ T cells in both the blood and gastrointestinal tract. Taken 
from (1). 
 1.2 Monocyte Role in HIV/SIV 
Blood monocytes originate in splenic and bone marrow reservoirs, enter blood 
circulation, and serve an immune function through the release of cytokines and phagocytosis (4).  
Three major monocyte subpopulations exist, and are defined by their expression of CD14 – a co-
receptor for lipopolysaccharide – and CD16 – a Fc Receptor.  Monocyte subpopulations, 
CD14+CD16-, CD14+CD16+, and CD14-CD16+, are referred to as classical, intermediate, and 
non-classical monocytes, respectively.  The relationship among these monocytes is unknown, 
and cells may be fated towards a particular subpopulation, or may mature from classical to 
intermediate to non-classical monocytes upon entry into the blood.  These three monocyte 
subpopulations differ in their kinetics of exit from the bone marrow into the blood (5), and in 
protein and gene expression profiles. 
 Classical monocytes are unique in that they enter peripheral tissues under non-
inflammatory conditions (6) and have higher phagocytic ability and release toxic superoxides 
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(7).  Monocyte chemotactic protein-1 receptor CCR2, the receptor for monocyte chemotactic 
protein with involvement in monocyte translocation from bone marrow to blood, is most highly 
expressed on the classical monocyte subpopulation, suggesting differences in migration and 
response to signals by different monocyte subpopulations (8).  Gene expression unique to 
classical or classical and intermediate monocytes is involved in positive regulation of cell 
proliferation, regulation of protein kinase cascades, endocytosis, and wound healing functions 
(9).   
Intermediate monocytes are transcriptionally intermediate between classical and non-
classical monocytes, but also unique in several aspects (9, 10).  Intermediate monocytes have the 
highest level of SIV replication of all monocytes (11).  Functions of intermediate monocytes 
include secreting reactive oxygen species, serving as antigen presenting cells, and contributing to 
inflammation (12).  Gene expression unique to the intermediate and non-classical or non-
classical monocytes includes genes involved in negative regulation of cell proliferation, cell 
activation, and regulation of T-cell activation (9), as well as genes involved in cytoskeletal and 
inflammatory cytokine gene networks (10).  Intermediate and non-classical monocytes are more 
susceptible to HIV infection than classical monocytes, suggesting their similarity to tissue 
macrophages (13).   
Further, gene expression in non-classical monocytes is most similar to expression by 
tissue-differentiated macrophages, illustrating this monocyte subpopulation as the most mature 
(9).  Non-classical monocytes serve a role as immune patrollers in the blood, mediated by their 
expression of high levels of adhesion receptors and integrin adhesion molecules (14).  Compared 
to other monocytes, non-classical monocytes express significantly higher levels of CCR5, the 
receptor for macrophage inflammatory protein 1α, and lack the expression of CCR2 (8).   
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 1.3 Monocyte Expansion in HIV/SIV 
Monocyte subpopulations further differ in their rate of turnover from bone marrow to the 
blood.  5-bromo-2'-deoxyuridine (BrdU) labeling of pre-monocytes in bone marrow shows that 
BrdU-labeled classical monocytes are the first to peak in blood, followed by intermediate, and, 
lastly, non-classical monocytes, illustrating turnover and kinetic differences among the 
subpopulations that is compatible with monocyte subsets representing stages of cell maturation 
(15).  The rate of monocyte turnover is significantly higher in SIV-infected macaques than 
uninfected controls, and strongly correlates with animal survival, making monocyte turnover a 
potentially useful predictor of disease progression (16).  Monocyte turnover also correlates with 
the severity of CNS terminal disease and distinguishes rapid and slow AIDS progressors (5).  
Thus, further characterization and phenotyping of monocyte populations that expand with SIV 
and HIV infection will help in understanding the functions of monocyte subpopulations and what 
their roles are in disease progression.    
 1.4 Macrophage Accumulation in HIV/SIV 
Macrophages are a heterogeneous myeloid population found in tissues, and most 
macrophages are a mature, tissue-differentiated cell type of blood monocytes (17).  Mediated by 
pro-inflammatory cytokines, blood monocytes bind to selectins and intercellular adhesion 
molecules expressed by endothelial cells to mediate transmigration into inflamed tissue (18).  
High levels of monocyte traffic across the endothelial barrier into peripheral tissues and the 
accumulation of macrophages in the tissue results in an expansion of cellular traffic across 
weakened barriers, including across the blood-brain barrier into the central nervous system 
(CNS) (19).  High levels of macrophage accumulation in the central nervous system (CNS), 
especially of inflammatory macrophages, is a defining feature of encephalitis (17, 20).  Within 
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the CNS of HIV+ persons, macrophages are the main cell type sustaining HIV infection, which 
makes this cell type a potential viral reservoir (21).  Because of the presence of virally infected 
macrophages in the brain that can persist even with ART and their recent immigration into 
tissues, it is critical to understand both tissue macrophages and their immature monocyte 
precursor.  HIV-infected macrophages can be sources of latent HIV infection, in which HIV 
DNA is integrated into the host DNA (1).  Viral sequencing indicates HIV compartmentalization 
in the brain of HIV-infected people and that the CNS contains residual virus throughout infection 
(22).  Chemotactic signaling increases monocyte- and macrophage-mediated inflammation 
following HIV replication within the brain, increasing the monocyte entry into tissue and 
macrophage accumulation (23).   
The role of macrophage accumulation and contribution to disease is thus integrally 
related to monocyte expansion and phenotype.  A unique inflammatory macrophage 
subpopulation, which is identified by the expression of the calprotectin protein, is absent in tissue 
without inflammation, lesions, or infection, and makes up over 80% of the infiltrating cells 
during SIV infection (24).  These inflammatory calprotectin-expressing macrophages, and 
monocytes, have a strong correlation with infection and disease, and thus are expected to play an 
important role in the inflammatory immune response. 
1.5 Calprotectin Structure 
Calprotectin, alternatively known by the names of the L1 antigen (25) and the cystic 
fibrosis antigen (26) is a 36.5 kDa protein heterodimer.  This calprotectin complex is formed by 
disulfide-linked MRP-8 and MRP-14 proteins (for which the encoding genes are referred to as 
S100A8 and S100A9, respectively) (27) (see X-ray crystal structure and binding sites of the 
complex below, Figure 2).  Further complex formation has illustrated the possibility of 
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homodimerization, trimerization, and tetramerization of these two subunits.  Calprotectin 
contains an EF hand motif on each of its subunits, which facilitate the calcium-binding function 
of the molecule (25), and the dimerization of the two subunits to form the calprotectin molecule 
is a calcium-dependent process (28).  In humans, the encoding subunits of calprotectin map to 
chromosome 1q21-25 (29).  Calprotectin also has zinc-binding function, which is found on the 
MRP-14 subunit and does not compete with this subunit’s calcium-binding function (30).  The 
MRP-14 subunit also has specific and high-affinity binding to heparan sulfate proteoglycans (31) 
and carboxylated glycans (32).  Because of this affinity and calprotectin expression on the 
surface of neutrophils during their activation, calprotectin may also play a role in cell 
extravasation into tissues (32). 
 
Figure 2.  Calprotectin Structure.  X-ray crystal structure illustrates the MRP-8 (green) and MRP-14 
(yellow) complex formation to form the calprotectin complex. S2 is the zinc-specific binding site and S1 is 
a zinc/manganese binding site.  Taken from (33). 
 
1.6 Calprotectin Expression in Neutrophils 
Calprotectin is strongly expressed by neutrophils and myeloid cells, and has limited 
expression in endothelial and epidermal cells (34).  Protein expression of calprotectin is highest 
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in neutrophils, where it is found primarily in the cytoplasm and comprises about 45% of the 
cytosolic proteins of this cell type (35).  About 96% of all granulocytes from healthy individuals 
are positive for calprotectin, and this expression is ~5% for eosinophils and <2% for basophils 
(36).  The substantial amount of calprotectin in neutrophil and monocyte cytoplasm has indicated 
the potential role of these cells as ‘calcium sinks’ (37), suggesting a role in protecting cells from 
harmful effects of long exposure to high calcium levels and intracellular inhibition of casein I 
and II, leading to a termination of cellular metabolic activity (38).  Through monocyte 
chemoattractant protein-1 (MCP-1), calcium has been shown to play a role in signaling in the 
inflammatory process during atherogenesis (39).  Another suggested intracellular activity of 
calprotectin is inhibition of casein kinase I and II, which is itself implicated in regular cellular 
transcription and translation.  Inhibition of these kinases would terminate cellular metabolic 
activity.  During calcium-dependent activation of neutrophils, calprotectin becomes 
phosphorylated and moves to the cell membrane (40).  In neutrophils, the MRP-14 subunit of 
calprotectin is specifically involved in promoting integrin-mediated cell adhesion (41).  Further, 
neutrophil exposure to MRP-14 results in an elevated and sustained increase in neutrophil 
adhesion to fibrinogen (42).  In vitro studies further show that the MRP-14 subunit of 
calprotectin increases neutrophil transmigration both in the presence and absence of 
chemoattractants (42).   
1.7 Calprotectin Expression in Tissue Macrophages 
Tissue macrophages expressing calprotectin are generally found near blood vessels, 
supporting the notion that this macrophage population is recently immigrated into tissue and has 
a blood monocyte origin (34).  Calprotectin is not expressed by normal tissue macrophages, but, 
under inflammatory conditions or with infection, a population of calprotectin-expressing 
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macrophages is present in the brain and CNS lesions (24).  Macrophage expression of the MRP-
14 subunit alone is especially associated with acute inflammation, while macrophage expression 
of MRP-8 and MRP-14 together is more associated with chronic inflammation (26, 43).  The 
number of macrophages expressing calprotectin is increased in liver tissues of those with 
hepatitis C infection, relative to uninfected controls (44).  In inflammatory neuropathies, 
including Guillain-Barré patients, the number of calprotectin-positive macrophages increases 
significantly (43).   
Macrophages in tissue lesions expressing calprotectin also represent an important and 
changing cell population.  Cardiovascular tissue immunostaining has shown calprotectin cell 
expression is most tightly associated with CD68+ macrophage-abundant lesions (45).  In human 
infection with T-cell lymphotropic virus type I, macrophages express calprotectin in active 
lesions with a short duration of illness, while macrophages lacked calprotectin expression in 
inactive chronic lesions (46).  Calprotectin expression may also occur under non-inflammatory 
disease states, including ischemic brain lesion formation, where a resident and non-inflammatory 
macrophage population known as microglia only express MRP-8 and MRP-14 within the first 
three days in lesions after infarction (47).  The lack of MRP expression after 3 days on these 
microglia suggests MRP expression is an early step in microglial activation and that their 
expression is very temporally distinct, with an integral role in lesion formation or the early stages 
of lesion expansion (47).  It is suggested that the loss of MRP-8/14 expression in microglia may 
be a result of cell transformation towards an ameboid cell type with phagocytic functions (47).  
The role of calprotectin-expressing macrophages in lesions underscores the role of this cell type 
in chronic disease inflammation and as a contributing cell type to active lesions.  Calprotectin 
expression is also associated with tissue destruction, and expression on muscle tissue 
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macrophages correlates with muscle fiber destruction (48).  Together, the expression of 
calprotectin by endothelial cells, neutrophils, and monocytes/macrophages suggests its important 
and widespread role in innate immune protection (49).   
1.8 Calprotectin Expression in Monocytes 
The calprotectin protein is present in the cytoplasm of virtually all monocytes (36), but is 
substantially less abundant there than in neutrophils, and comprises about 1% of monocyte 
cytosolic protein (35).  Measures of calprotectin expression between disease states and health is 
substantially less studied in circulating monocytes than in macrophages.  However, increased 
numbers of blood monocytes expressing calprotectin are associated with mild acute pancreatitis 
(50). 
  In those with muscle fiber necrosis, about 90% of monocytes expressing the resident 
macrophage marker CD68+ were also positive for calprotectin expression (48).  However, in 
vitro stimulation with various inflammatory stimuli – LPS, TPA, and IFN-γ – do not increase the 
number of monocytes expressing calprotectin, but, rather, increase the level of calprotectin 
expression on monocytes already expressing calprotectin, suggesting that calprotectin-expressing 
monocytes become activated, rather than a calprotectin-negative monocyte expressing 
calprotectin as a part of its activation (34).  Monocyte expression of either MRP-14 alone or the 
entire calprotectin complex is associated with cells having increased surface expression of the 
adhesive molecule CD11b (51).  In culture, addition of a pro-inflammatory cytokine that 
activates monocytes shows that monocytes reach peak calprotectin expression 2-3 days 
following stimulation (34).  However, in the absence of stimulation, monocyte culture conditions 
do not appreciably alter calprotectin expression by freshly isolated monocytes within three days 
(19).  In vitro monocyte stimulation with Mycobacterium results in fivefold higher levels of 
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supernatant calprotectin (52).  Furthermore, monocyte incubation with MRP-14 results in 
cytokine release of the pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and chemokines 
growth-related oncogene α, IL-8, MCP-1, and MIP-1α, (42).  In contrast, neutrophil incubation 
with MRP-14 was unable to induce these same cytokine and chemokine releases (42), supporting 
calprotectin-expressing monocytes as particularly important in inflammation. 
1.9 Antibody Recognition of Calprotectin 
Multiple antibodies against calprotectin have been developed, with a range of 
specificities, including against MRP-8, MRP-14, or both subunits.  The monoclonal antibody 
MAC387, in use by our lab, was first developed in mouse and demonstrates strong reactivity 
against infiltrating histiocytes (27).  The MAC387 antibody has specificity for the MRP-14 
protein, and also recognizes the MRP-8/MRP-14 calprotectin heterocomplex (53, 54).  The 
antibody 27E10 has also been shown to recognize the calprotectin complex, but neither subunit 
alone (55).  Another antibody against calprotectin, mAb 5.5, also reacts only with the MRP-
8/MRP-14 complex, but neither independent subunit, suggesting a conformational change with 
heterodimer formation leading to the formation or exposure of the recognized antigen (53).  In 
addition to calcium-dependent heterodimer formation, antibody recognition of calprotectin is 
calcium-dependent (53), and neither MRP-8 nor MRP-14 contain a signal or membrane-anchor 
sequence (26), which suggests the calcium-dependency for calprotectin transmigration to the cell 
surface. 
1.10 Calprotectin Secretion 
Without inflammatory stimuli, calprotectin protein is predominantly in the cytoplasm.  
Following cellular activation, calprotectin is secreted.  Adherence of monocytes to extracellular 
matrix proteins fibronectin and collagen in vitro results in a rapid translocation of calprotectin to 
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the cell membrane, suggesting that monocyte adhesion and entry into tissues is associated with 
calprotectin surface expression (56).  The activation of protein kinase C and an intact tubulin 
network are required for the process of calprotectin secretion from activated monocytes (57).  
Secretion of calprotectin by monocytes can be induced by interaction with stimulated endothelial 
cells, TNF activation, or the presence of extracellular matrix proteins, but interaction with resting 
endothelial cells is not sufficient to cause calprotectin secretion (58), resulting in the additional 
recruitment of other inflammatory myeloid cells.   
1.11 Calprotectin Function 
Upon secretion, calprotectin has a pro-inflammatory role (59), and is present at high 
levels in the extracellular space with inflammation, including numerous chronic diseases (60).  
The MRP-8 subunit of calprotectin is a ligand for TLR4 and, through interaction with the TLR4-
MD2 complex, amplifies pro-inflammatory phagocyte activation (61).  In vitro work shows that 
a calprotectin-expressing monocyte preferentially transmigrates across a blood-brain barrier 
model (62).  Coinciding with surface expression of calprotectin, interleukin-6, tumor necrosis 
factor α, and superoxide anion release contribute to the pro-inflammatory response (56).  
Calprotectin also has an inflammatory role in connective tissues, as demonstrated by calprotectin 
inhibiting fibroblast growth and inducing fibroblast apoptosis in vitro (63).  Calprotectin secreted 
from activated macrophages also prevents myoblast proliferation and differentiation, and 
correlates with myofiber degeneration (48).  Calprotectin inhibits the growth of monocytes and 
macrophages, and even leads to lysis of cells from a tumor line in vitro, demonstrating an anti-
proliferative role as a negative growth regulator (64).  A contributing factor to the anti-
proliferative function of calprotectin is explained by its inhibition of intracellular casein kinase 
II, which is involved in cell growth (37).  Together, these functions induced by calprotectin in 
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vitro contribute to cell accumulation observed in vivo in response to calprotectin, and may also 
help explain the pro-inflammatory role of calprotectin-expressing monocytes/macrophages as it 
relates to inflammation (60).  Further, calprotectin is shown to have antimicrobial activity, and is 
shown in vitro to inhibit the growth of fungi, bacteria, and human cell lines (37).  Antimicrobial 
activity by calprotectin is at least partially explained by its competition for zinc ions, which are 
required for microbial growth (65).  This expression contributes to individual cells that express 
calprotectin being more resistant to bacterial binding and entry (66). 
1.12 Soluble Calprotectin As a Marker of Inflammation & Disease 
Calprotectin release by neutrophils and monocytes and its accumulation in blood has 
been associated with a variety of diseases, underscoring the importance of calprotectin secretion 
with inflammation.  Serum and plasma are both the remaining portion of blood after blood cells 
have been removed; serum further has clotting factors removed.  Calprotectin levels in serum 
and plasma significantly correlate with a substantial number of active infections and 
inflammatory diseases.  In HIV+ people, serum calprotectin is elevated in those with AIDS 
relative to those in earlier stages of infection, and thus calprotectin serves as a biomarker for 
acute infection in immunocompromised individuals (67).  Plasma levels of calprotectin in those 
with tuberculosis infection are elevated relative to uninfected controls, and correlate with the 
severity of tuberculosis disease progression (52).  Calprotectin levels are also elevated in the 
serum of individuals with multiple sclerosis, and, within these patients, are elevated in those 
experiencing acute relapse relative to those experiencing stable disease remission (68).  In serum, 
MRP-14 concentrations are significantly elevated in those with prostate cancer (69).  Plasma 
calprotectin levels are also elevated in obese individuals, relative to non-obese controls (70) and 
in those with type 2 diabetes mellitus (71).  Active juvenile rheumatoid arthritis results in a 5-
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fold increase in serum calprotectin levels relative to those with juvenile rheumatoid arthritis in 
remission, which is similar in level to those without the disease (58).  Serum calprotectin is also 
elevated in those with Chron’s disease, and, within these patients, higher disease activity was 
associated with higher calprotectin levels in serum (72).  Serum calprotectin levels are 
significantly elevated in patients with systemic lupus erythematosus relative to healthy 
individuals, and significantly correlate to an index of disease activity (73).  Calprotectin levels 
can also be prognostic of survival, with high levels in plasma correlating with a poor survival 
rate in those with alcohol-induced cirrhosis (74).  With significantly higher calprotectin levels in 
inflammatory disease states, and also with more severe disease states or progression, the 
measurement of calprotectin has an extremely important role as a relatively non-invasive 
diagnostic tool. 
1.13 Solubilized Calprotectin In HIV 
Previous studies have looked at some correlates with blood calprotectin in the context of 
HIV.  In HIV+ persons, serum calprotectin levels do not correlate with viral load (75).  However, 
secreted calprotectin levels do correlate with other parameters closely tied to immune cell 
dysfunction.  Serum calprotectin levels are inversely correlated with CD4+ T cell count in 
individuals with CD4+ T cell counts over 50 x 10^6 per liter, with increasing levels of 
calprotectin correlating with lower CD4+ T cell counts and thus with immunodeficiency (75).  
Serum calprotectin is significantly elevated in both AIDS and non-AIDS asymptomatic HIV-
infected patients relative to HIV-negative individuals (67, 75).  Further, serum calprotectin levels 
are significantly lower during acute HIV infection than in patients with AIDS, and are suggested 
as arising as part of the neutrophilic antimicrobial defense, resulting in immune activation during 
the immune dysregulation of AIDS (67).  Serum calprotectin is elevated in HIV patients with 
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moderate to severe clinical conditions associated with HIV, as compared to uninfected 
individuals (49).  In the most severe CDC classification of HIV based on clinical conditions, 
significantly higher MRP-14 serum levels were found in HIV+ people relative to uninfected 
people, but no differences were found in the MRP-8 subunit between these groups (49).  This 
association of MRP-14 indicates an association with both progressive immunodeficiency and 
clinical events, including opportunistic infections (49).  In contrast, serum levels of the MRP-8 
subunit of calprotectin alone were significantly lower in those with HIV infection relative to 
uninfected people (67).  A comparison of HIV-positive persons with and without oral candidiasis 
found significantly elevated saliva calprotectin levels in those with oral candidiasis disease, 
suggesting a defensive role of calprotectin in HIV complications (76).  In those with HIV 
infection, serum calprotectin also significantly correlates with neopterin, a pro-inflammatory 
molecule produced by stimulated monocytes/macrophages (49). 
Treatment of HIV with the anti-retroviral reverse transcriptase inhibitor Zidovudine 
results in an expected increase in CD4+ T cells and a decrease in viral load while serum 
calprotectin levels increase (75).  In both asymptomatic HIV-positive patients and HIV-positive 
patients that have progressed to AIDS, treatment with Zidovudine concomitantly resulted in an 
initial rise in serum calprotectin levels for the first 3-6 months, followed by calprotectin levels 
returning to baseline within 12 months after beginning Zidovudine treatment (75).  A study 
found no difference in MRP-8, MRP-14, or calprotectin serum levels between HIV+ people that 
did or did not receive Zidovudine treatment (49). This study also found that significantly lower 
calprotectin responses were associated with HIV+ people with an AIDS-defining infection 
within the first year following Zidovudine treatment, indicating high calprotectin responses are 
related to a lessened risk of AIDS-defining complications (75).  A correlation was found between 
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the maximum calprotectin response to Zidovudine and the length of survival, suggesting that 
serum calprotectin levels may be a prognostic marker of the function of anti-retroviral therapy 
(75).  This suggests that calprotectin secretion plays an important role both in acute HIV 
infection and in the early stages following anti-retroviral treatment. 
1.14 Monocyte & Macrophage Calprotectin Expression in HIV & SIV Infection 
Microarray analysis of RNA reveals that gene expression for the two subunits of 
calprotectin – S100A8 and S100A9 – are expressed greater than 2-fold in classical monocytes 
relative to either intermediate and non-classical monocytes (9).  The higher calprotectin RNA 
expression of classical monocytes is present in uninfected rhesus macaques and SIV-infected 
rhesus macaques both 26 days after infection and terminally with AIDS (9).  However, at the 
protein level in uninfected macaques, intermediate monocytes have the highest calprotectin 
expression, followed by classical monocytes, and nearly nonexistent expression by non-classical 
monocytes (77).  This high expression in classical and intermediate monocytes suggests a 
potential link between this monocyte subset and the inflammatory MAC387+ macrophage.  At 
the protein level, calprotectin expression on both classical and non-classical monocytes tends to 
decrease from pre-infection levels to AIDS (24), but a characterization of monocyte expression 
of calprotectin throughout the course of HIV or SIV infection is lacking.  However, this does 
give insight into the specific monocytes that are expressing and potentially secreting calprotectin 
during the HIV/SIV inflammatory response. 
Macrophages staining positive with the anti-calprotectin MAC387 antibody (MAC387+) 
are a unique inflammatory tissue subpopulation and have distinct surface expression, which 
includes high CD16 expression, while lacking CD68, CD163, and CCR2 expression (24).  These 
MAC387+ macrophages are absent from the central nervous system (CNS) of SIV-uninfected 
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macaques, but widespread in CNS tissue by 21 days after SIV infection and their accumulation 
characterizes early CNS inflammation (78).  Expression of calprotectin is limited to this recently 
infiltrating macrophage population, and is absent on both CD68+HAM56+CD163- resident and 
CD163+CD68+ perivascular macrophage populations (24).  In SIV infection, MAC387+ 
macrophage accumulation within the CNS is compartmentally distinct, with early accumulation 
in the meninges and choroid plexus and late accumulation in the perivascular space and 
encephalitic lesions with the progression to AIDS (78).  In the CNS of SIV-infected rhesus 
macaques, MAC387+ macrophages represent the majority of all recently infiltrated cells, and 
30% of these macrophages were infiltrated within 48 hours (24, 78), further supporting the role 
of this macrophage as inflammatory and blood monocyte-derived.  Rhesus macaques infected 
with SIV also have elevated MAC387+ macrophages during early acute disease within the 
lymph nodes (79).   
In terminal HIV+ patients, MAC387+ macrophages are unique to those with encephalitis 
(24).  The large majority of recently emigrated cells present in lesions of SIV-infected rhesus 
macaques are macrophages that express calprotectin, present in early acute infection, and are 
suggestive of a monocytic cell origin (5).  In these patients, MRP-8 expression was found in 
addition to the calprotectin complex, contrasting the lesions of SIV-infected macaques (24).  
Higher CD163+/MAC387+ macrophages is indicative of AIDS disease progression both in SIV 
infection (78), supporting MAC387+ macrophages as having a role in the early inflammatory 
response and lesion formation.  Specifically in the case of SIV infection, the MAC387+ 
macrophage is an inflammatory cell type that is not productively infected, and this cell type 
contributes more to lesions in mild encephalitis relative to severe encephalitis (24).  
Immunohistochemistry work shows that in encephalitic lesions, calprotectin-expressing 
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macrophages are the dominant tissue macrophages during acute infection and inflammation, but 
there is a shift in lesion macrophage contribution in chronic and severe encephalitic lesions 
towards CD68+ macrophages and HIV/SIV infected macrophages (24).  Phenotyping the 
MAC387+ monocyte and tracking changes in its expression and levels of soluble calprotectin in 
blood will likely play a key role in understanding how this crucial cell type contributes to the 
progression of SIV and HIV disease. 
1.15 Open Questions 
Prior to this work, an immunophenotype analysis of the calprotectin-expressing blood 
monocyte throughout the course of HIV or SIV infection was lacking.  This research 
demonstrates the MAC387+ monocyte present in SIV infection as CD163+, CD169+, CCR2+, 
CCR5-, and CX3CR1-.  The expansion of inflammatory, calprotectin-expressing macrophages 
with SIV infection and elevated blood calprotectin levels in a variety of inflammatory disorders 
underlines the importance of this cell type in HIV and SIV disease progression.  Limited 
immunophenotyping has been performed on the MAC387+ macrophage, but this analysis is 
lacking in monocytes, which offer a window into disease progression instead of only the 
inflammatory conditions after necropsy.  While it is established that the classical monocyte 
subset has the highest calprotectin gene expression, it is unknown how calprotectin protein 
expression corresponds with different monocyte subsets and immune expression.  The issue 
addressed in this thesis and associated work is the contribution of MAC387+ monocytes to SIV 







(1) How does the level of secreted calprotectin in blood change over the course of 
infection? 
(2) What is the phenotype of the MAC387+ monocyte and does this change over the 
course of infection? 
(3) What monocyte gene expression changes occur in coordination with calprotectin 
gene expression increases? 
It is hypothesized that levels of secreted calprotectin will peak in blood during acute 
infection, or approximately the first three weeks following SIV infection.  Calprotectin 
expression on monocytes is expected to accordingly decrease during this time, due to secretion 
of the molecule, and be highest on the classical monocyte subpopulation.  Immunophenotype and 
gene expression of the classical MAC387+ monocyte are expected to be similar to that of 
inflammatory MAC387+ macrophage observed in tissue, particularly during the acute phase of 
SIV infection. 
In order to characterize the calprotectin-expressing monocyte, PBMCs isolated from 
rhesus macaques infected with SIV over the course of infection were immunostained for specific 
markers of interest.  Non-human primates infected with SIV that are CD8+ T cell-depleted to 
achieve rapid AIDS progression and a higher incidence of encephalitis have routinely been used 
as model of HIV and AIDS (9, 24, 78, 80).  This will both allow a characterization of the 
MAC387+ monocyte in terms of classical, intermediate, or non-classical monocytes, as well as 
measuring the changes in immune marker expression over time.   
In order to relate monocyte expression of calprotectin to calprotectin levels in blood, 
ELISAs were performed to measure plasma calprotectin levels in the same animals.  The 
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calprotectin ELISA kit used in this study has previously been used to measure serum calprotectin 
levels in several primate species, including rhesus macaques infected with bacteria of the genus 
Burkholderia (81, 82), and measuring calprotectin increases with infection.  In order to better 
understand the role of calprotectin levels in blood and expression on monocytes in SIV disease 
progression, animals were used with varying severities of disease that ranged from no AIDS to 
SIV encephalitis (SIVE).  In order to connect MAC387+ monocyte expression and secreted 
calprotectin, MAC387+ monocyte expression was compared with plasma calprotectin levels.  
This thesis describes the phenotype of calprotectin-positive monocytes, the changes of these cells 
over the course of infection, the expression of these cells on the three recognized monocyte 
subpopulations, the levels of plasma calprotectin throughout SIV infection and other gene 




CHAPTER 2:  MATERIALS & METHODS 
2.1 Animal Cohorts 
Peripheral blood mononuclear cells (PBMCs) and plasma samples taken from blood were 
analyzed from 5 adult rhesus macaques (Macaca mulatta).  Animals were infected by a 1 mL IV 
of 1.1 ng/mL SIVmac251.  In order to achieve a more rapid progression and higher incidence of 
AIDS, animals were subcutaneously administered a CD8-depleting antibody at 10 mg/kg 
bodyweight at 6 days post-infection and intravenously administered the CD8 antibody at 5 
mg/kg bodyweight at 8 and 12 days post-infection.  One animal, IP79, was found dead in its cage 
at 63 days after SIV infection, with AIDS and CMV infection.  The remaining animals were 
euthanized between 106 and 126 days after infection by pentoarbital overdose upon presentation 
of AIDS-defining criteria described in (24), which includes dramatic weight loss and 
opportunistic infections.   
Animal ID AIDS SIVE Other Pathology DPI at Necropsy 
JD29 Yes Yes Pneumonia & CMV 126 
LB12 Yes Yes CMV Infection 115 
JE87 Yes Yes (mild) None 119 
IP79 Yes No CMV Infection 63 
JL37 No No N/A 106 
Table 1.  Animal ID, disease pathology of whether an animal had AIDS, SIVE, and/or other relevant 
disease or infection, and length of survival for the animal cohort used for plasma calprotectin ELISA and 
PBMC flow cytometry data. 
 
2.2 Measuring Extracellular Calprotectin 
 Plasma calprotectin levels were determined with the Calprotectin (serum) ELISA RUO 
kit from DRG International (cat. # EIA-5111R), according to the manufacturer’s protocol.  
Plasma samples were diluted 1:50 in order to fall within the detection limits of this assay, which 
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have a minimum of 3.9 ng/mL and a maximum of 250 ng/mL, and absorption was determined at 
450 nm against 630 nm.  
2.3 Flow Cytometric Analysis of MAC387 on Blood Monocytes 
PBMC samples were washed with 20% FBS – 80% PBS washes, and incubated with a 
surface antibody cocktail, which was made from the antibodies shown below in Table 2 







Antibody Clone Vendor 
MAC387 RPE 0.2 MAC387 (IgG1 isotype) Biorad 
L/D QD605 1 N/A Fisher 
CD3 APCCY7 5 SP34-2 BD Pharmigen 
CD20 APCCY7 1 2H7 BioLegend 
HLA-DR ECD 2 Immu-357 Beckman Coulter 
CD14 PB 2.5 M5E2 BD Pharmigen 
CD16 PECY7 0.2 3G8 BD Pharmigen 
CD163 PERCPCY5.5 10 GHI/61 BioLegend 
CX3CR1 BV650 10 2A9-1 BioLegend 
CCR2 A700 5 48607 RnD 
CCR5 PEC5 5 2D7/CCR5 BD Pharmigen 
CD169 APC 10 7-239 BD Pharmigen 
BrdU FITC 2 N/A BD Pharmigen 
 
Table 2.  List of antibodies used for PBMC staining, including vendor, volume used per sample, and 
specific clone for each antibody. 
 
Following a cell membrane permeabilization with BD Cytofix/Cytoperm Buffer, cells 
were incubated with the MAC387 antibody in order to determine intracellular expression of the 
MAC387 antigen.  For the samples from timepoints when animals received BrdU injections, a 
nuclear permeabilization step was performed with BD Cytoperm Plus Buffer, and cells were 
incubated with the anti-BrdU antibody.  Lastly, cells were fixed with 1% paraformaldehyde.  
Data was acquired with a FACS Aria (BD Biosciences), and FlowJo software was used to 
analyze the data.  An unstained sample was used for compensation for all markers in order to 
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minimize the effect of autofluorescence on data.  Monocytes were initially selected for based on 
side and forward scatter, followed by negative selection for L/D stain against free amines in 
compromised membranes, CD3, and CD20, and positive selection for HLA-DR.  Analysis gates 
were then set that differentiated monocytes into classical, intermediate, and non-classical 
monocytes on the basis of CD14 and CD16 expression.  Monocytes were then 
immunophenotyped within these subpopulations for expression of MAC387, and the total 
monocyte subpopulation was immunophenotyped for BrdU (in relevant samples), CD163, 
CD169, CCR2, CX3CR1, and CCR5.  See below for a representative figure of the flow gating 
scheme. 
 
Figure 3.  Monocyte Gating Scheme.  Beginning in the top-left, monocytes were selected on a forward 
scatter/side scatter dot plot, selected for negative expression of a L/D stain and negative for CD3 and 
CD20, and positively selected for the expression of HLA-DR.  Lastly, monocytes were positively selected 
for based on CD14 and/or CD16 expression.  Data on total monocytes used this Boolean gated cell 
population, and, for data on specific monocyte subsets – classical, intermediate, and non-classical – cell 






2.4 Gene Expression Analysis 
 Transcriptomic data was also utilized which was generated by others from SIV-infected 
rhesus macaques from 5 treatment groups:  no treatment (n=2), placebo (n=2), ART only (n=6), 
MGBG only (n=4), and MGBG+ART (n=5).  Timepoints for samples were 20 DPI, 49 DPI, and 
necropsy.  Since blood draws on day 20 happened prior to the first treatment, these animals are 
considered untreated.  Monocytes were isolated and RNAseq was performed on monocyte 
samples for each treatment/timepoint, not by single cell sequencing.  Monocyte samples had 
ribosomal RNA depleted and mRNA libraries were prepared for sequencing on the Illumina 
HiSeq system.  Reads were trimmed using Trimmomatic (v 0.36), underwent quality control, and 
were aligned to the rhesus macaque transcriptome with STAR_2.6.1a_08-27.  Quantification of 
transcript abundance was made with RSEM (v1.2.31).  Differential expression analysis between 
samples was performed with DESeq2 and unsupervised random forest clustering was performed 
with an ad hoc R script.  Because of including samples from different studies, direct comparisons 
were only possible between MGBG only and Placebo; and among ART only, MGBG+ART, and 
Untreated groups.  Differential expression analysis was made between cohorts at the same time 
points, and between time points for the same cohort.  A false discovery rate of p= 0.05 was used.  
Adapter sequences were trimmed from results with Trimmomatic (v 0.36).  Gene networks 





CHAPTER 3:  RESULTS 
3.1 Plasma Calprotectin Measurement by ELISA 
In order to look at the role of calprotectin secretion and blood levels of calprotectin as 
they associate with SIV disease progression, plasma calprotectin levels were first measured by 
ELISA.  Figure 4A shows plasma levels of calprotectin during early infection, when levels are 
lower.  Figure 4B shows plasma calprotectin levels later in infection, from 20 DPI through 
necropsy, which is associated with substantially higher levels in blood.  The 0 time point here 
serves as a baseline for each animal, because plasma for this timepoint was taken prior to the 
injection of SIVmac251.  Four out of five of the animals had increases in plasma calprotectin 
within a week of infection.  For all animals, peak plasma calprotectin was either at 20 days post-
infection (which is the point of peak viral load), or at necropsy.  All animals also had an increase 
from their second to last data point to chronic late-stage disease at necropsy, most of which were 
euthanized with AIDS-associated disease.  The difference in scale between Figures 4A and 4B 
here show the higher calprotectin levels that are present from peak infection (around 3 weeks 
post-infection) until necropsy, compared to early time points.   
Rhesus macaques progressing to AIDS (n=4) had an average of an 12.0-fold increase 
from 0 DPI to 20 DPI, with fold-increase ranging from 3.08-fold to 59.7-fold.  Those macaques 
progressing to AIDS (n=4) had an average of an 18.0-fold increase from 0 DPI to necropsy, with 
fold-increase ranging from 2.58-fold to 44.9-fold.  Standard deviations for plasma calprotectin 
levels for macaques with AIDS (n=4) was 209.8, 4769.4, and 4630.9 for the respective time 
points of 0 DPI, 20 DPI, and necropsy.  Animals with SIVE (n=3) had an average of a 17.6-fold 
increase from 0 DPI to 20 DPI, with fold-increase ranging from 5.10-fold to 59.7-fold.  Animals 
with SIVE (n=3) had an average of a 19.0-fold increase from 0 DPI to necropsy, with fold-
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increase ranging from 2.58-fold to 44.9-fold.  Standard deviations for plasma calprotectin levels 
for macaques with SIVE (n=3) was 155.7, 5204, and 4924 for the respective time points of 0 
DPI, 20 DPI, and necropsy.  In contrast, these same time points for macaques without SIVE 
(n=2), had a fold-increase between 0 DPI and 20 DPI of1.03-fold to 3.08-fold.  The range for 
fold-increase for macaques without SIVE (n=2) between 0 DPI and necropsy was 1.79-fold to 
16.5-fold.  The standard deviation for plasma calprotectin levels for macaques without SIVE 
(n=2) was 2441, 1491, and 2940 for the respective time points of 0 DPI, 20 DPI, and necropsy.  
Statistics are shown in Table 3. 
A   
B     C   
Figure 4. Plasma calprotectin.  Plasma calprotectin levels over the course of SIV infection, broken down 
by animal.  Panel A shows plasma calprotectin for all data points for all animals, from 0 DPI to 
necropsy.  Panels B and C together contain all data present in panel A, but separated for clearer 
illustration of the early data points within the first 15 days of SIV infection, and therefore with different 
maximum values on the x-axis.  Panel B shows data values from timepoints 0-14 DPI, and panel C shows 
data values for all later timepoints, beginning at 20 DPI.  Red crosses above each animal in panels A and 
C indicate necropsy timepoint.  The dashed horizontal line in all panels represents the average baseline 
(pre-infection) plasma calprotectin of all five animals of 1192.2 ng/mL. 
 

























































































A  B  
C  
Figure 5.  Plasma Calprotectin Comparisons Between Pathologies.  Using the same data as presented in 
Figure 4, panel (A) compares the average of all animals progressing to AIDS (n=4) to the animal without 
AIDS (n=1).  Panel (B) compares the average of all animals with SIVE (n=3) to the averages of animals 
without SIVE (n=2).  Panel (C) further breaks down those animals with AIDS into IP79, which 
progressed to AIDS within 63 days, to all other AIDS animals (n=3), which were necropsied with AIDS 
between 106-126 DPI.  For each timepoint, the mean of animals for a particular disease state (i.e. AIDS) 
is shown, with bars indicating the standard error of the mean.  The solid horizontal line in all panels 





























































































  AIDS (n=4) No AIDS (n=1) 
Timepoint Mean SD Mean SD 
0 DPI 452 210 4154 0 
6/7 DPI 1339 655 3241 0 
12/14 DPI 761 754 565 0 
20 DPI 5410 4769 4267 0 
49 DPI 3608 1548 2730 0 
91 DPI 1545 1096 4317 0 
Necropsy 8143 4631 7432 0 
 
  SIVE (n=3) No SIVE (n=2) 
Timepoint Mean SD Mean SD 
0 DPI 368 156 2428 2441 
6/7 DPI 1033 288 2749 697 
12/14 DPI 500 668 1053 690 
20 DPI 6493 5204 3213 1491 
49 DPI 3879 1776 2762 46 
91 DPI 1545 1096 4317 0 
Necropsy 6994 4924 9511 2940 
 
  Rapid Progressor (n=1) Slow Progressors (n=3) 
Timepoint Mean SD Mean SD 
0 DPI 702 0 368 156 
6/7 DPI 2256 0 1033 288 
12/14 DPI 1541 0 500 668 
20 DPI 2159 0 6493 5204 
49 DPI 2795 0 3879 1776 
91 DPI     1545 1096 
Necropsy 11590 0 6994 4924 
 
Table 3.  Mean and standard deviation for each pathology subset of data presented in Figure 5.  Data 
points at one week (either 6 or 7 DPI) were aggregated for comparison.  Data at two weeks (either 12 or 




Table 4.  Plasma calprotectin levels throughout SIV infection, broken down by pathology state as shown 
in Figure 5 to show the 25th/75th percentiles of data.  The SIVE group is a subset of the AIDS group, since 
SIVE is an AIDS-defining characteristic, and thus progression of an animal to SIVE inherently indicates 
a progression to AIDS as well; three of four animals progressing to AIDS in this study also had SIVE. 
 
In order to better understand plasma calprotectin levels in the context of SIV disease 
progression, plasma calprotectin levels were grouped by progression to SIVE, AIDS, or, for 
animals with AIDS, their rapidity of progression.  For the comparison of animals based on AIDS 
progression, macaques with AIDS (n=4) were compared to the macaque that did not progress to 
AIDS ( only animal JL37).  Here, there is not an appreciable difference between plasma 
calprotectin levels or in trends of increasing or decreasing from two weeks after infection until 
necropsy.  However, as shown in Figure 5A, the initial level of plasma calprotectin is more than 
four-fold higher for the sole animal which did not progress to AIDS (JL37), relative to the 
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average of the other four animals progressing to AIDS (JD29, LB12, JE87, and IP79).  To look 
at disease progression another way, comparisons were made between animals progressing to 
SIVE (n=3) and those without SIVE (n=2); animal IP79 progressed to AIDS, but did not have 
SIVE.  Here, again, there is little difference between the two animal groups with regards to 
whether or not they developed SIVE, with an initial increase in plasma calprotectin, followed by 
a more drastic increase by 20 days post-infection, levels decreasing slightly, and increasing again 
by necropsy.  However, by comparing IP79, which progressed to AIDS nearly twice as fast as all 
other animals with AIDS, to those taking over 100 days after infection to reach AIDS, there is a 
much earlier drastic increase in plasma calprotectin, as shown in Figure 5C. 
In addition to looking at the changes in plasma calprotectin level over the course of SIV 
infection, calprotectin levels in plasma were also compared to other metrics known to be 
associated with disease progresson in HIV or SIV infection.  As demonstrated by Burdo, et al., 
(2010), following BrdU injection in SIV-infected macaques, early monocyte expression of BrdU 
differentiates between slow and rapid AIDS progressors and the percentage of monocytes at 
necropsy that express BrdU correlates with the severity of SIVE (83).  Here, a comparison of the 
time points for which BrdU staining was available in PBMCs showed a modest positive trend 
between plasma calprotectin level and the number of BrdU+ monocytes (Figure 6A) (p=0.2862).  
A modest positive trend was also present between the percentage of monocytes that are BrdU+ 




A  B  
Figure 6.  Plasma Calprotectin & Monocyte Turnover.  Data points in panel (A) are corresponding time 
points for the total number (raw value) of monocytes expressing the thymidine analog BrdU, following a 
BrdU injection 24 hours to sample collection with the level of plasma calprotectin, as measured by 
ELISA.  Data points in panel (B) are corresponding time points for the percent of total monocytes 
expressing BrdU with the level of plasma calprotectin.  For both panels, p-value and correlation 
coefficient, r, are given.  Neither trend reaches significance at the p=0.05 threshold. 
A comparison of the plasma viral load and plasma calprotectin levels in SIV-infected 
animals, however, does show a significant positive correlation (p=0.0175) between these two 
parameters, and higher viral load is positively correlated with higher levels of plasma 
calprotectin, as shown in Figure 7. 
 
Figure 7.  Plasma Calprotectin & Viral Load.  A comparison of plasma viral load values with plasma 
calprotectin, with each data point representing the same animal and timepoint during infection.  There is 
a signficant (p=0.0175) positive correlation between the viral load and calprotectin in plasma. 
 
3.2 MAC387 Expression and Immunophenotyping by Flow Cytometric Analysis  
In order to address defining MAC387 monocytes and changes in MAC387+ monocytes 
during the course of infection, PBMCs were isolated from rhesus macaque blood samples, 
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stained with a panel of fluorescent antibodies for use in flow cytometry to gate for the monocyte 
population of interest, and immunophenotyped.  By looking over the timecourse of infection at 
the expression of MAC387 on total monocytes, as measured by mean fluorescence intensity 
(MFI) by flow cytometry, no consistent trends were found that fit the entire cohort (Figure 8).  
However, the sole animal that did not progress to AIDS (JL37) had a unique several-fold 
increase in MAC387 protein expression at 20 days post-infection. 
 
Figure 8.  MAC387 Expression in Peripheral Blood Monocytes.  Total monocyte expression of MAC387 
over the course of infection is shown, separated by animal.  Two massive outliers are included:  a 
CD14+CD16- MFI value of 43166 for animal JL37 and a CD14+CD16- MFI value of 228500 for animal 
IP79 at 6 DPI.  These massive values are the reason for the broken y-axis.   
 
However, by taking an average of all animals and separating MAC387 MFI data for 
classical, intermediate, and non-classical monocytes, there is relatively stable expression of 
MAC387 throughout infection until at least day 91, and then a consistent drop for all animals at 
necropsy (Figure 9).  There is modest change in MAC387 MFI among timepoints 20 DPI, 49 
DPI, and 91 DPI.  However, the 91 DPI MAC387 MFI values are several-fold greater than their 
corresponding necropsy values.  The 91 DPI MAC387 MFI values are 4.57-, 3.54-, and 3.30-fold 
greater than necropsy values for classical, intermediate, and non-classical monocytes, 
respectively. 































Figure 9.  MAC387 Expression in Monocyte Subpopulations.  The CD14+CD16- monocyte is the 
classical monocyte, the CD14+CD16+ monocyte is the intermediate monocyte, and the CD14-CD16+ 
monocyte is the non-classical monocyte.  For each timepoint, data were averaged for all animals.  Two 
massive outliers are included:  a CD14+CD16- MFI value of 43166 for animal JL37 and a 
CD14+CD16- MFI value of 228500 for animal IP79 at 6 DPI.  These massive values are the reason for 
the broken y-axis.  Exclusion of these data points would result in intermediate monocytes having the 
highest MAC387 MFI value for all timepoints.  Inclusion of these two data points results in classical 
monocytes having the highest MAC387 MFI at 0 and 6 DPI, and the highest MAC387 MFI by 















































  CD14+CD16- 
Timepoint Mean MFI SD 
0 DPI 22271 29550 
6/7 DPI 114307 160786 
20 DPI 1692 2137 
49 DPI 1983 779 
91 DPI 2673 2153 
Necropsy 585 227 
   
  CD14+CD16+ 
Timepoint Mean MFI SD 
0 DPI 6648 6565 
6/7 DPI 2208 1736 
20 DPI 2477 2879 
49 DPI 2558 910 
91 DPI 3010 2431 
Necropsy 876 228 
   
  CD14-CD16+ 
Timepoint Mean MFI SD 
0 DPI 1247 166 
6/7 DPI 1407 1001 
20 DPI 1918 2217 
49 DPI 1672 599 
91 DPI 2069 1547 
Necropsy 627 242 
Table 5.  Mean and standard deviation values for MAC387 MFI for each time point, separated for 
monocyte subpopulation, as shown in Figure 9.  In the absence of the outliers mentioned in the figure 
legend of Figure 9, the mean for CD14+CD16- 0 DPI would be 1376 and for CD14+CD16- 6/7 DPI 
would be 614. 
 
BrdU-labeling and expression of the CD163, CD169, CCR2, CX3CR1, and CCR5 
immunomarkers were then analyzed over the course of infection.  In order to determine the 
phenotype of the MAC387+ monocytes, and how they change over the course of SIV infection, 
the total monocyte population (classical, intermediate, and non-classical) were divided based on 
positive expression of MAC387, or lack thereof.  Within the monocyte population staining 
positive for MAC387, the relative MFI for BrdU and each of the of the immunomarkers 
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measured was graphed against respective timepoint, as shown in Figure 10.  The MAC387+ 
population consistently included about 70-90% of monocytes, indicating that this is the 
percentage of monocytes that are MAC387+ and express calprotectin.  Because of the limited 
availability of samples with BrdU injection prior to sample acquisition, BrdU staining was only 
available at 20 days post-infection and at necropsy.  Between these time points, there was a 
modest increase in BrdU expression by MAC387+ monocytes (Figure 10A).  MAC387+ 
monocyte expression of CD163, CD169, and CCR2 followed similar patterns of expression with 
an initial increase in expression, followed by a decrease at 91 days post-infection, and increasing 










A  B                    
       C  D             
E  F  
Figure 10.  Monocyte Immunophenotyping.  Following the gating selection for total monocytes, this 
population was further divided into MAC387+ and MAC387- monocyte populations.  Using the 
MAC387+ monocyte subpopulation, immunophenotype marker MFI was looked at longitudinally.  For 
each immunomarker, data for all animals was averaged for each timepoint and standard error bars are 
shown.  Figures are from n=5 animals, but not every timepoint has all five samples available.  Following 
compensation for markers CX3CR1 and CCR5 (Figures 10E and 10F), numerous data points generated a 
negative MFI value.  Such negative values are a physical impossibility, and so are treated as a ‘0’ MFI 
for this arbitrary unit and negative expression for the monocytes of respective animals at the respective 
timepoint. 




































































































Table 6.  Values for standard deviation and range for respective immunophenotype markers for 
respective timepoints.  Based on available samples and BrdU injection schedule, BrdU standard 
deviation, range, and as illustrated in Figure 10 use n=5 at 20 DPI and n=3 at Necropsy.  For all other 
markers, available data used is from n=2 at 0 DPI; n=2 at 6 DPI; n=5 at 20 DPI; n=3 at 49 DPI; n=3 at 
91 DPI; and n=3 at necropsy.  For data points that had a ‘negative’ mean MFI as shown in Figure 10 
and were treated as 0 MFI, the range and standard deviation shown in this table are for the values prior 
to standardization as a value of 0. 
 
 
3.3 Gene Expression Analysis Among SIV Infection Treatments and Timepoints 
With the aim of determining genes and functions associated with elevated levels of 
calprotectin gene expression, RNAseq data were analyzed for flow-sorted monocytes from five 
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treatment groups:  MGBG only (n=4), Placebo (n=2), ART only (n=6), MGBG+ART (n=5), and 
Untreated (n=2).  Data were acquired from three infection timepoints for analysis:  20 DPI, 49 
DPI, and necropsy.  Gene expression was compared among time points within the same 
treatment group and among treatment groups at the same timepoint.  RNAseq comparisons ART-
20-49; ART-UNTREATED-D49; ART-UNTREATED-Nec; MGBGART-20-49; and 
MGBGART-20-Nec show significant differential expression of both S100A8 and S100A9 (the 
two subunits of calprotectin).   
These five gene expression comparisons were analyzed to look at the genes, gene 
networks, and functions that increased in expression in tandem with gene expression increases of 
S100A8 and S100A9.  Of the identified gene ontology biological processes associated with 
genes present here, APOBEC3A is highly expressed by monocytes and macrophages with 
interferon stimulation and IL1B is produced by activated macrophages.  APOBEC3A protein 
product has restriction activity against viruses and foreign DNA and IL1B is a pro-inflammatory 
cytokine important in neutrophil influx and activation.  Figure 11, below, shows the gene 
networks generated by https://string-db.org.  From a random assortment of genes of this size, 
there is an expectation of three connections.  The 47 observed connections shown below more 
than meet the threshold for significance.  The protein-protein interaction (PPI) enrichment p-
value of <1.0e-16 measures the significance of biological interaction of protein products for the 
respective genes, and, in Figures 11 and 12, shows the high functional relatedness of identified 
genes.  This parameter looks at the significance of related function among genes of interest.  In 
the five abovementioned conditions/timepoints where S100A8 and S100A9 increase expression, 
there is a relatedness among a large number of those genes also increasing in expression.  
However, the functional related network does not have any established connections to S100A8 or 
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S100A9.  Such upregulated genes and their functions may be important in the MAC387+ 
monocyte or the monocyte population at large with acute infection.  See Table 7 for a more 
complete list of the gene functions of genes with increased expression with increased 
calprotectin gene expression. These represent the genes most in direct correlation to S100A8 and 
S100A9.   
 
Figure 11.  Stringent Network of Genes Upregulated with Calprotectin Upregulation.  Gene networks 
for genes differentially expressed in all 5 condition comparisons for which both S100A8 and S100A9 
were differentially expressed.  Among these genes, by random chance, there is an expectation of only 3 
connections, but the 47 connections identified represents a PPI enrichment p-value of <1.0e-16.  This 
means that the gene list pulled out is not random.  Significance threshold is genes with an absolute fold 
change of greater than or equal to 1.3 and a permutation FDR of less than or equal to 0.05.  Fold-change 
thresholds are arbitrary, but log2(fold change) values <-1.3 or >1.3 are usually reported in papers as 
significant (summary of written statement by collaborator Dr. Marco Salemi).  Connecting lines indicate 
the two genes have known interactions from curated databases (teal) or experimental determination 
(purple); predicted interactions by gene neighborhood (green), by gene fusions (red), or gene co-
occurrence (blue); or by textmining (light green), co-expression (black), or protein homology (light blue). 
 
However, by considering a lower threshold, any genes with increased expression in a 
minimum of four of the five conditions under which S100A8 and S100A9 had increased 
expression, Figure 12 was generated.  Here, the genes under consideration increased from 30 
genes, in Figure 11, to 75 genes, shown below in Figure 12.  The expected number of 
connections here based on a random assortment of genes is 14, but the 162 observed gene 
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connections illustrates the connected and functionally associated nature of the genes more highly 
expressed with high calprotectin gene expression.  Figure 12 illustrates several things.  First, the 
strong interconnectivity in the gene network in Figure 12 (well above a threshold for significance 
of interrelated genes) illustrates that monocytes with elevated calprotectin expression also have 
increases in the expression of other genes, which are functionally related that makes the 
calprotectin-expressing monocyte a unique and inflammatory cell type with a consistent 
functional role.  Secondly, in Figure 12, CD163 – a strong indicator of cell activation – is the 
functional link between the calprotectin gene subunits S100A8 and S100A9 and the central hub 
of genes with elevated expression, indicating the role of CD163 and cell activation in the 
inflammatory calprotectin-expressing monocyte subpopulation.  Thirdly, the gene network in 
Figure 12 reveals which genes and which functional networks are involved in monocytes with 
elevated calprotectin expression.  Details on these functions are explored in depth in the 




Figure 12.  Broad Network of Genes Upregulated with Calprotectin Upregulation.  Gene networks for 
genes differentially expressed in at least 3 of the 5 condition comparisons for which both S100A8 and 
S100A9 were differentially expressed.  Among these genes, by random chance, one would expect only 14 
connections, but the 162 connections identified represents a PPI enrichment p-value of <1.0e-16.  
Significance threshold is genes with an absolute fold change of greater than or equal to 1.3 and a 
permutation FDR of less than or equal to 0.05.  Fold-change thresholds are arbitrary, but log2(fold 
change) values <-1.3 or >1.3 are usually reported in papers as significant (summary of written statement 
by collaborator Dr. Marco Salemi).  Connecting lines indicate the two genes have known interactions 
from curated databases (teal) or experimental determination (purple); predicted interactions by gene 
neighborhood (green), by gene fusions (red), or gene co-occurrence (blue); or by textmining (light 
green), co-expression (black), or protein homology (light blue). 
 
Using the expanded gene list presented in Figure 12, I further examined those genes that 
are expressed by, or play a role in, monocytes and monocyte-derived macrophages.  Below, 
Table 7 lists these genes, their involvement in monocytes & macrophages in terms of expression, 






Gene Myeloid Expression Function 
 Differentially Expressed Genes in 5 
Conditions (Figure 11) 
 
APOBEC3A highly expressed in monocytes & 
macrophages upon interferon stimulation 
restriction activity against viruses & foreign DNA 
CHIT1 occurs only at a late stage of differentiation 
of monocytes and activated macrophages; 
secreted by activated macrophages 
degrades chitin of microorganisms 
IFI27 upregulated in monocyte-derived 
macrophages by HIV-1 Tat & Vpr proteins 
involved in signaling pathway leading to apoptosis; antiviral 
activity in innate immunity 
IL1B produced by activated macrophages proinflammatory cytokine; induces neutrophil influx & 
activation, T-cell activation & cytokine production, and B-cell 
activation and antibody production 
ISG15 expressed by monocytes chemotactic activity towards neutrophils, antiviral activity 
SIGLEC1 macrophage-restricted adhesion molecule receptor for clathrin-dependent endocytosis; adhesion 
molecule on macrophages which mediates sialic-acid 
dependent cell binding 
 Differentially Expressed Genes in 4 
Conditions (Figure 12) 
 
ADAMDEC1 upregulated during differentiation of 
monocytes into macrophages; highly 
expressed in macrophages 
induced by LPS; modulates macrophage polarization 
AZU1 Monocyte chemotactic activity Encodes a preprotein with antibacterial/cytotoxic activity 
against gram-negative bacteria; may have role in monocyte 
recruitment 
CD163 marker of monocyte/macrophage lineage; 
exclusive to this lineage; soluble form is a 
marker of disease 
receptor involved in clearance of hemoglobin/haptoglobin 
complexes; shed with LPS exposure 
CPM expression associated with monocyte to 
macrophage differentiation 
control of hormone & growth factor activity; involved in 
degradation process of extracellular proteins 
FCGR1A expressed by macrophages & monocytes; 
downregulated on these cells by HIV-1 Nef 
protein 
Fc Gamma receptor involved in both innate and adaptive 
immunity 
IDO1 expressed by monocytes & macrophages involved in amino acid catabolism; modulates T cell behavior 
and is involved in self-tolerance in immunity 
MPO expressed in monocyte liposomes antimicrobial activity through production of hypohalous 
acids; involved in phagocytosis 
OSM synthesized by stimulated monocytes inhibits proliferation, and regulates cytokine production 
SERPINB2 present in monocytes/macrophages metabolism regulation & responds to increases in cytosolic 
calcium *note that S100A8 & S100A9 are calcium-binding, 
and their dimerization to form calprotectin is calcium-
dependent 
TLR8 expressed and undergoes proteolytic 
processing in both monocytes and 
monocyte-derived macrophages 
role in pathogen recognition (through PAMPs) and activating 
innate immunity 
Table 7. Gene name, role with monocytes/macrophages, and function for genes with differential 








CHAPTER 4:  DISCUSSION 
Blood calprotectin levels have been extensively studied across a variety of diseases, 
infections, and disease severities, and calprotectin levels in blood are consistently associated with 
disease and inflammation.  However, monocyte expression and secretion of calprotectin is 
understudied.  Using rhesus macaques infected with SIV, I analyzed longitudinal plasma 
calprotectin.  A previous study in HIV blood samples had shown some of the blood calprotectin 
level trends, but only had limited timepoints (75).   
The work in this thesis presents blood calprotectin levels from 0 DPI until necropsy at 
late-stage chronic disease in SIV-infected rhesus macaques and includes breakdowns for 
different disease comparisons.  Figure 4 illustrates the large increase in calprotectin levels from 
pre-infection to necropsy, which, in some cases, increase by greater than ten-fold, suggesting an 
important role of the calprotectin protein in SIV infection and disease progression.  Calprotectin 
secretion by both neutrophils and monocytes contributes to the level of extracellular calprotectin 
in the blood, and neutrophils are responsible for the majority of such calprotectin (82).  
Elucidating the difference in contribution of secreted calprotectin from monocytes versus that 
from neutrophils would be a difficult endeavor, but here is best addressed by a comparison of 
secreted levels to calprotectin protection expression observed on monocytes.  Following the 
exclusion of dead cells, CD3+, and CD20+ cells by flow gating, neutrophils can be selected for 
by CD66b expression (84), and cytometry for a measure of cell numbers.  Further work should 
look into the changes in calprotectin expression on neutrophils and the number of neutrophils 
expressing calprotectin throughout SIV infection.  Monocyte expression of calprotectin would 
logically decrease with calprotectin secretion, which is a process that occurs during the 
inflammatory processes associated with SIV infection, and thus is expected to have an inverse 
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relationship over the course of infection.  In fact, the two biggest trends of calprotectin 
expression in monocytes are a decrease in expression from 0 DPI to 6 DPI, and a decrease in 
expression in samples immediately prior to necropsy (Figure 9).  Figure 4 illustrates the 
increasing secreted calprotectin levels in blood from 0 DPI to 6 DPI, and the sharp increases in 
all animals with the necropsy time point, suggesting important monocyte contribution to the 
calprotectin levels observed by ELISA.  Peak viremia occurs around 21 DPI, and the large 
increases in plasma calprotectin for all animals coinciding with this time point suggests an 
activation of the MAC387+ monocyte and secretion of calprotectin at this timepoint.  For all 
animals, the maximum calprotectin level in blood was either at 20 DPI or at necropsy, which 
indicates that animals may take one of two general paths with respect to monocyte secretion of 
calprotectin:  a rapid response to virus, or a persistent secretion that accumulates, and 
accumulates very rapidly in chronic disease progression and the development of AIDS. 
 Further analysis of plasma calprotectin levels show that, while disease progression to 
AIDS (Figure 5A) does not have much difference in calprotectin levels over the course of 
disease, calprotectin levels could play a significant diagnostic role in predicting the rapidity of 
AIDS progression.  A greater than four-fold increase in plasma calprotectin occurred in animal 
IP79 (Figures 4B and 5C), which was found dead in cage at 63 DPI with AIDS-defining 
characteristics and had a higher necropsy calprotectin value than the necropsy calprotectin level 
in any other animal shows the importance of the level of calprotectin secretion.  The high 
calprotectin levels in Figure 5C, which compares plasma calprotectin in the rapid AIDS 
progressor IP79 to those animals taking over 100 days to progress to AIDS, suggests that the 
shedding of calprotectin and its accumulation in blood may be a driver or effect of progression 
towards AIDS and indicate an earlier progression to this disease state.  The level of calprotectin 
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in blood prior to infection may have an important effect on disease progression and opportunistic 
infections.  It is counterintuitive that the single animal which did not progress to AIDS – JL37 – 
would be the only animal to have a substantial decrease in plasma calprotectin within the first 
week following infection, while all other animals had increases in plasma calprotectin from their 
pre-infection baseline.  A high plasma calprotectin level in blood during health (pre-infection) 
may be an indicator of a robust immune system and high expression and secretion of calprotectin 
by MAC387+ monocytes.  Animal JL37 has a baseline blood calprotectin level of over four 
times that of any of the other animals (Figure 4A), all of which have tightly clustered calprotectin 
baselines.  In the plasma calprotectin ELISA data, the necropsy level of calprotectin is always 
elevated relative to the immediately preceding data timepoint.  The progression to AIDS, which 
in this case corresponds to necropsy timepoints, seems to be indicated by a spike in calprotectin 
secretion that remains elevated with late-stage disease. 
The association established between monocyte turnover and the severity of SIVE 
highlights the importance of monocyte turnover and immigration into tissues during SIV disease 
progression (83).  Here, moderate trends between plasma calprotectin and both the number of 
BrdU+ monocytes, and the percent of all monocytes expressing BrdU, suggest that the secretion 
of calprotectin during immune defense is involved with monocyte activation that leads to 
monocyte/macrophage infiltration into tissues by a calprotectin-expressing monocyte (Figure 6).  
Better powered studies will be needed to determine if this trend is meaningful, and whether the 
secretion of calprotectin is involved in the immune defense response associated with monocyte 
activation.  However, the positive and significant correlation between plasma viral load and 
plasma calprotectin level could indicate that calprotectin is released, at least in part, in response 
to presence of virus or high levels of infected cells (Figure 7).  This may further indicate that in 
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the case of SIV infection, calprotectin molecules play an antiviral role, which would be 
supported by their established antimicrobial role (65). 
This study is the first that looks at longitudinal expression of calprotectin protein on 
monocytes, immunophenotypes these cells to define them and their changes over time, and is 
able to relate this data to plasma levels of calprotectin for corresponding animals and timepoints.  
The several-fold increase in MAC387 expression by animal JL37 at 20 days post-infection, 
shown in Figure 8, suggests that an initially strong response in calprotectin expression in 
monocytes may either be a driver or an indicator of resilience to disease progression.  As shown 
in Figure 9, there is a clear drop in mean expression of MAC387 on all three monocyte 
subpopulations that distinctly occurs at necropsy.  This suggests that something is occurring as 
an animal is approaching AIDS disease in monocytes where expression stops, or calprotectin is 
secreted that represents an extreme loss of immune control.  The monocyte immunostaining 
work presented here at the protein level parallels the gene expression work of Nowlin et al., 
(2018) that shows the highest calprotectin expression in classical monocytes, which is also 
observed in Figure 9.   
Despite the highest gene expression of calprotectin by classical monocytes, this work 
suggests that at the protein level, intermediate monocytes may be playing an especially 
significant role with regards to calprotectin secretion.  Results shown in Figure 9 illustrate how 
high the initial calprotectin expression by intermediate monocytes is, which then substantially 
decreases within a short period following SIV infection.  A possible explanation here is that the 
intermediate monocyte subpopulation is secreting calprotectin.  This monocyte subpopulation 
then continues to have the highest expression of calprotectin with chronic disease (samples taken 
immediately prior to necropsy), at which point there is a notable decrease in calprotectin 
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expression by all monocytes.  The final decrease in calprotectin expression by monocytes, 
coupled with the high plasma levels observed, suggests that monocytes may reach an 
“exhaustion” of calprotectin secretion with the extreme immune disfunction associated with 
progression to AIDS.  Already high blood calprotectin levels and the monocyte’s inability to 
secrete more calprotectin may further exacerbate the immune disfunction of AIDS. 
Decreases in  CD163, CD169, and CCR2 around 91 DPI – shortly before reaching 
chronic AIDS disease – supports the MAC387+ monocyte/macrophage as an important, 
activated, and inflammatory cell type in acute infection, which decreases with late-stage chronic 
disease.  The susceptibility of cells to HIV or SIV infection through the coreceptor CCR5, and 
the low expression of CCR5 on classical and intermediate monocytes, and the data in Figure 10F 
showing no CCR5 expression by MAC387+ monocytes supports the notion of the MAC387+ 
monocyte as the precursor to the MAC387+ macrophage, which does not sustain viral infection.    
The decrease of CD163, CD169, and CCR2 around 91 days post-infection, prior to rising to the 
highest expression of any of these markers at necropsy, suggests that MAC387+ monocytes 
begin to decrease their expression of these markers prior to immune disfunction that results in 
AIDS (Figure 10).  The increases in CD169 expression – an adhesion molecule – and CCR2 –
involved in monocyte chemotaxis – by MAC387+ monocytes over the course of SIV infection 
also suggests a changing role of this cell type:  one of adhesion and infiltration into tissue with 
the inflammatory response.  This, coupled with increases in expression of activation marker 
CD163, suggests this monocyte is likely to enter tissue with inflammation, and is a likely 
candidate for the MAC387+ tissue macrophage observed with infection and inflammation.  This 
MAC387+ monocyte is also observed to have high turnover both at peak viremia (20 DPI) and at 
necropsy, suggesting a persistent inflammatory response both in early and late disease. 
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In addition to immunophenotyping these MAC387+ monocytes with a handful of useful 
immune-markers, changes in gene expression were examined by RNAseq of bulk populations.  
Given the caveat that single-cell sequencing was not performed, some potentially interesting 
connections were observed.  Looking across timepoints within a particular treatment, and across 
different treatments at a particular timepoint, revealed several conditions for which gene 
expression of S100A8 and S100A9 – which encode the two calprotectin subunits – increases.  Of 
course, these genes were not alone in increased expression in these conditions, and an analysis of 
which other genes had upregulated expression in tandem added to potentially define the 
MAC387+ monocyte and its function.  An important feature to notice in Figures 11 and 12 is 
that the genes that change in coordination with calprotectin  are highly interconnected.  This 
suggests particular genes with related function may change in coordination with calprotectin 
gene upregulation and their protein products may suggest functions of MAC387+ monocytes or 
other monocytes during the acute phase of SIV infection.   
Whether some of these genes are changing in response to changes in calprotectin 
regulation, or calprotectin, along with these other genes, are all changing in response to 
particular environmental stimuli, such as infection, is not known.  With a stringent threshold of 
which genes change in every instance (treatment or timepoint comparison) under which 
calprotectin significantly changes, the significance of gene interconnection reaches a protein-
protein enrichment interaction of p = <1.0e-16.  Analysis of the roles of these genes in myeloid 
cells reveals two general functions important to the immune response to infection:  an 
antiviral/antibacterial role, and pro-inflammatory chemotaxis.  In tandem with calprotectin 
upregulation, APOBEC3A, CHIT1, IFI27, and ISG15 have antiviral or antibacterial roles.  
Further, the upregulation in IL1B observed as well is likely responsible for amplifying the 
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response by inducing the activation of several immune cell types and the production of pro-
inflammatory cytokines.  ISG15 and SIGLEC1 play roles in myeloid cells for chemotaxis and 
serve as adhesion molecules, respectively.   
By expanding the genes that may have important associated functions with the expression 
of calprotectin in monocytes, a less stringent approach was taken to additionally include any 
genes changing expression in tandem with calprotectin in at least 80% of conditions where 
calprotectin had differential regulation.  This expansion confirms earlier conclusions that the 
MAC387+ monocyte has a role in antiviral activity during SIV infection, with AZU1 and MPO 
having established antimicrobial function.  Other genes are present in these cases as well, 
including genes that serve roles in combating infection.  CPM is involved in extracellular protein 
degradation and TLR8 serves a role in pathogen recognition.  One especially important gene in 
the analysis in Figure 12 is CD163, which connects S100A8 and S100A9 to the central hub of 
activity, thus linking these proteins to a large portion of the genes that change in expression.  
CD163 is the scavenger receptor for hemoglobin-haptoglobin and is an important biomarker of 
disease.  Solubilization of CD163 occurs with monocyte/macrophage activation, and CD163 
levels in plasma are elevated in neurocognitively impaired HIV patients (85).  CD163 is 
especially important in its relationship with MAC387 in the context of SIV and HIV, where a 
higher ration of CD163:MAC387 macrophages in lesions is associated with progression to SIV 
encephalitis, as opposed to animals without encephalitis and animals sacrificed after three weeks 
of SIV infection (78).   
A notable difference between the expression of these two markers on monocytes is that 
MAC387 expression sharply decreases with necropsy, which is the point with the lowest 
MAC387 expression across all monocyte subpopulations (Figure 9), while CD163 expression 
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increases with necropsy, which is the timepoint with highest expression (Figure 10).  Analysis of 
monocytes and plasma protein levels may serve as a noninvasive measure of clinical conditions 
of a person over the course of HIV infection and the success of an anti-retroviral regimen.  This 
analysis of RNAseq data is limited and does not look specifically into any particular treatment or 
timepoint.  The five sample comparisons with changes in S100A8 and S100A9 are ART-20-49; 
ART-UNTREATED-D49; ART-UNTREATED-Nec; MGBGART-20-49; and MGBGART-20-
Nec.  Looking at two of these comparisons – ART-UNTREATED-D49 & ART-UNTREATED-
Nec – highlights differences observed between ART and untreated at two different time points.  
The higher expression of calprotectin with ART treatment at these two different time points 
suggests the improvements observed with ART (including a decrease in viral load) are associated 
with an increase in the protective function of calprotectin and cells expressing calprotectin.  
Future work should look into seeing if this observed increase in calprotectin RNA expression in 
later-stage SIV infection is also observed at the protein level with ART treatment.  The other 
three sample comparisons with increases in calprotectin gene expression – ART-20-49; 
MGBGART-20-49; and MGBGART-20-Nec – illustrate the higher calprotectin expression at 
peak infection relative to both 49 DPI and necropsy.  The inflammatory monocyte/macrophage is 
present at high levels in tissue in acute infection.  Higher calprotectin expression at the gene 
level around 20 DPI relative to both 49 DPI and necropsy supports the notion of an expanding 
inflammatory population, and that this cell population is responsible for a large portion of tissue 
entry by monocytes during early inflammation. 
This study does have limitations in relating the findings to the role of the MAC387+ 
monocytes in HIV infection in people.  With a sample size of five animal, this work identifies 
potentially important trends relating to MAC387+, but requires validation with a greater sample 
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size that will increase the statistical power of results.  Additionally, the ELISA measurements of 
secreted calprotectin in blood may not be exclusively secreted from monocytes, but a substantial 
proportion may be the result of neutrophil secretion, which, in and of itself, does not change the 
inflammatory nature of the implications of this data.  However, this data must be used with 
caution when relating measured secreted levels specifically to monocytes and correlation of the 
two.  One must also consider that the MAC387 antibody from Biorad has specificity for the 
MRP-14 subunit alone, in addition to the MRP-8/MRP-14 calprotectin complex, and thus 
MAC387 must cautiously be used to indicate the calprotectin complex (53, 54).  Further, the 
monocytes analyzed by RNAseq here were not analyzed by single-cell sequencing, which may 
provide an inappropriate average of cells and gene expression when there are important 
subpopulations, which may be lost in this method of cell sequencing for gene expression. 
Future experiments could take several forms.  A particularly interesting future step would 
be to relate terminal MAC387+ monocyte expression and plasma calprotectin level with 
MAC387+ macrophage staining and distribution.  Understanding this particular connection 
would allow analysis of tissue damage – especially lesion formation and accumulation of 
inflammatory cells – to parameters in blood that would be less invasive.  Another particularly 
useful future strategy would be to use flow gating to select for MAC387+ and MAC387- 
monocytes to get a more complete picture of the gene expression differences between these cell 
types, and to see if the gene expression changes observed matches these observations in protein 
expression.  Using the principle of MAC387+ cell isolation, the unique technique of laser capture 
microdissection for selective isolation of cells based on particular immunostaining could further 
be used to select for MAC387+ and MAC387- macrophages in tissue, and for MAC387+ cells 
contributing to lesions, versus those not in lesions, to further characterize the gene expression of 
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MAC387+ myeloid cells.  One of the most relevant future studies for better understanding gene 
expression of MAC387+ monocytes would be to specifically incorporate MAC387+ and 
MAC387- monocytes for comparison, both among treatments and among infection timepoints.  
This work greatly advances our understanding of calprotectin in the context of SIV infection.  
Future steps to further advance this work could be used to relate individual monocyte 
subpopulations and MAC387+ monocytes with the population of MAC387+ infiltrating 
macrophages observed with infection and lesion formation, and to expand the 








Methods S2.1 Sample Storage 
Approximately 2 mL blood samples for respective timepoints were obtained from the 
animals and ethylenediaminetetraacetic acid was added as an anticoagulant.  Blood samples were 
centrifuged in Ficoll in order to separate PBMCs and plasma.  PBMCs were stored in in 10% 
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